Stocktoria
Anixa Biosciences Inc ANIX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1983-10-07
Anixa Biosciences Inc statistics & valuation
Market cap$94.9M
P / B6.3×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -6586.2% | -5243.3% | — | -2565.6% |
| Net margin | — | -5978.1% | -4671.9% | — | -2530.1% |
| Return on assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% |
| Return on equity | -72.1% | -62.8% | -40.3% | -46.8% | -36.6% |
| Current ratio | 8.08 | 8.54 | 12.50 | 14.83 | 28.35 |
| Revenue growth | — | 0.0% | — | — | — |
Source: SEC EDGAR filings · CIK 0000715446 · as of 2025-10-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.